Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: Pharmacoeconomics, Vol. 34, No. 5, 05.2016, p. 447-461.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches
AU - Hughes, D.
AU - Charles, J.M.
AU - Dawoud, D.M.
AU - Edwards, R.T.
AU - Holmes, E.A.
AU - Jones, C.L.
AU - Parham, Paul
AU - Plumpton, Catrin
AU - Ridyard, C.olin
AU - Lloyd-Williams, Huw
AU - Wood, E.M.
AU - Yeo, Seow
PY - 2016/5
Y1 - 2016/5
N2 - Trial-based economic evaluations are an important aspect of health technology assessment. The availability of patient-level data coupled with unbiased estimates of clinical outcomes means that randomised controlled trials are effective vehicles for the generation of economic data. However there are methodological challenges to trial-based evaluations, which include the collection of reliable data on resource use and cost, choice of health outcome measure, calculating minimally important differences, dealing with missing data, extrapolating outcomes and costs over time and the analysis of multinational trials. This review focuses on the state of the art of selective elements concerning the design, conduct, analysis and reporting of trial-based economic evaluations. The limitations of existing approaches are detailed and novel methods introduced. The review is internationally relevant but with a focus towards practice in the UK.
AB - Trial-based economic evaluations are an important aspect of health technology assessment. The availability of patient-level data coupled with unbiased estimates of clinical outcomes means that randomised controlled trials are effective vehicles for the generation of economic data. However there are methodological challenges to trial-based evaluations, which include the collection of reliable data on resource use and cost, choice of health outcome measure, calculating minimally important differences, dealing with missing data, extrapolating outcomes and costs over time and the analysis of multinational trials. This review focuses on the state of the art of selective elements concerning the design, conduct, analysis and reporting of trial-based economic evaluations. The limitations of existing approaches are detailed and novel methods introduced. The review is internationally relevant but with a focus towards practice in the UK.
U2 - 10.1007/s40273-015-0371-y
DO - 10.1007/s40273-015-0371-y
M3 - Article
VL - 34
SP - 447
EP - 461
JO - Pharmacoeconomics
JF - Pharmacoeconomics
SN - 1170-7690
IS - 5
ER -